Linical Co., Ltd. (2183.T)
JPY 294.0
(2.8%)
JPY 294.0
(2.8%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 725.72 Million JPY | -42.25% |
| 2022 | 1.25 Billion JPY | 15.73% |
| 2021 | 1.08 Billion JPY | 139.48% |
| 2020 | 453.43 Million JPY | -54.89% |
| 2019 | 1 Billion JPY | -17.13% |
| 2018 | 1.21 Billion JPY | -34.32% |
| 2017 | 1.84 Billion JPY | -13.25% |
| 2016 | 2.12 Billion JPY | 5.78% |
| 2015 | 2.01 Billion JPY | 129.54% |
| 2014 | 876.71 Million JPY | 24.15% |
| 2013 | 706.2 Million JPY | -29.61% |
| 2012 | 1 Billion JPY | 37.68% |
| 2011 | 728.72 Million JPY | 152.29% |
| 2010 | 288.84 Million JPY | -39.92% |
| 2009 | 480.75 Million JPY | -12.52% |
| 2008 | 549.56 Million JPY | 8.8% |
| 2007 | 505.09 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -66 Million JPY | -178.1% |
| 2023 Q1 | 112.05 Million JPY | -78.3% |
| 2023 Q3 | 219.98 Million JPY | -28.85% |
| 2023 FY | 725.72 Million JPY | -42.25% |
| 2023 Q4 | 84.5 Million JPY | -61.59% |
| 2023 Q2 | 309.17 Million JPY | 175.92% |
| 2022 FY | 1.25 Billion JPY | 15.73% |
| 2022 Q4 | 516.36 Million JPY | 40.74% |
| 2022 Q3 | 366.9 Million JPY | -8.33% |
| 2022 Q2 | 400.24 Million JPY | 1592.88% |
| 2022 Q1 | -26.81 Million JPY | -110.76% |
| 2021 Q1 | 145.73 Million JPY | -40.71% |
| 2021 Q2 | 361.94 Million JPY | 148.37% |
| 2021 Q3 | 328.99 Million JPY | -9.1% |
| 2021 Q4 | 249.23 Million JPY | -24.24% |
| 2021 FY | 1.08 Billion JPY | 139.48% |
| 2020 Q2 | 336.71 Million JPY | 323.4% |
| 2020 Q3 | 21.66 Million JPY | -93.57% |
| 2020 FY | 453.43 Million JPY | -54.89% |
| 2020 Q4 | 245.78 Million JPY | 1034.67% |
| 2020 Q1 | -150.72 Million JPY | -211.59% |
| 2019 Q2 | 441.55 Million JPY | 240.86% |
| 2019 Q1 | 129.54 Million JPY | -38.71% |
| 2019 Q3 | 299.07 Million JPY | -32.27% |
| 2019 Q4 | 135.06 Million JPY | -54.84% |
| 2019 FY | 1 Billion JPY | -17.13% |
| 2018 FY | 1.21 Billion JPY | -34.32% |
| 2018 Q4 | 211.36 Million JPY | -39.57% |
| 2018 Q3 | 349.76 Million JPY | -38.12% |
| 2018 Q2 | 565.19 Million JPY | 552.29% |
| 2018 Q1 | 86.64 Million JPY | -82.62% |
| 2017 Q4 | 498.52 Million JPY | -2.02% |
| 2017 FY | 1.84 Billion JPY | -13.25% |
| 2017 Q2 | 585.76 Million JPY | 130.95% |
| 2017 Q3 | 508.77 Million JPY | -13.14% |
| 2017 Q1 | 253.62 Million JPY | -46.93% |
| 2016 FY | 2.12 Billion JPY | 5.78% |
| 2016 Q3 | 530.11 Million JPY | -30.21% |
| 2016 Q2 | 759.54 Million JPY | 110.34% |
| 2016 Q4 | 477.88 Million JPY | -9.85% |
| 2016 Q1 | 361.1 Million JPY | -17.3% |
| 2015 FY | 2.01 Billion JPY | 129.54% |
| 2015 Q4 | 436.65 Million JPY | -1.54% |
| 2015 Q3 | 443.5 Million JPY | -47.4% |
| 2015 Q2 | 843.16 Million JPY | 191.66% |
| 2015 Q1 | 289.09 Million JPY | -23.65% |
| 2014 FY | 876.71 Million JPY | 24.15% |
| 2014 Q4 | 378.64 Million JPY | 85.0% |
| 2014 Q3 | 204.67 Million JPY | -0.64% |
| 2014 Q2 | 205.99 Million JPY | 135.7% |
| 2014 Q1 | 87.39 Million JPY | -62.47% |
| 2013 Q1 | 83.92 Million JPY | -72.16% |
| 2013 FY | 706.2 Million JPY | -29.61% |
| 2013 Q3 | 164.72 Million JPY | -26.69% |
| 2013 Q4 | 232.85 Million JPY | 41.36% |
| 2013 Q2 | 224.69 Million JPY | 167.73% |
| 2012 Q3 | 176.43 Million JPY | -36.98% |
| 2012 Q1 | 245.47 Million JPY | -8.14% |
| 2012 Q2 | 279.95 Million JPY | 14.05% |
| 2012 Q4 | 301.43 Million JPY | 70.85% |
| 2012 FY | 1 Billion JPY | 37.68% |
| 2011 FY | 728.72 Million JPY | 152.29% |
| 2011 Q1 | 26.79 Million JPY | -44.88% |
| 2011 Q2 | 240.43 Million JPY | 797.28% |
| 2011 Q3 | 194.27 Million JPY | -19.2% |
| 2011 Q4 | 267.21 Million JPY | 37.54% |
| 2010 FY | 288.84 Million JPY | -39.92% |
| 2010 Q2 | 145.83 Million JPY | 91.73% |
| 2010 Q1 | 76.06 Million JPY | -47.63% |
| 2010 Q3 | 18.33 Million JPY | -87.43% |
| 2010 Q4 | 48.61 Million JPY | 165.17% |
| 2009 Q1 | 210.86 Million JPY | -22.67% |
| 2009 FY | 480.75 Million JPY | -12.52% |
| 2009 Q4 | 145.25 Million JPY | 601.61% |
| 2009 Q3 | -28.95 Million JPY | -118.85% |
| 2009 Q2 | 153.59 Million JPY | -27.16% |
| 2008 Q4 | 272.67 Million JPY | 251.67% |
| 2008 Q2 | 122.26 Million JPY | 0.0% |
| 2008 FY | 549.56 Million JPY | 8.8% |
| 2008 Q3 | 77.53 Million JPY | -36.58% |
| 2007 FY | 505.09 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | -21.598% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | 246.06% |
| GNI Group Ltd. | 13.1 Billion JPY | 94.464% |
| Trans Genic Inc. | 89.43 Million JPY | -711.445% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 150.894% |
| Soiken Holdings Inc. | -610 Million JPY | 218.97% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | 193.915% |
| AnGes, Inc. | -11.96 Billion JPY | 106.064% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 164.751% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 107.618% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | -595.811% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | 183.956% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 164.972% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 157.506% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | 190.879% |
| RaQualia Pharma Inc. | -337.36 Million JPY | 315.115% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 160.218% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 154.337% |
| PeptiDream Inc. | 6.77 Billion JPY | 89.285% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 137.603% |
| Ribomic Inc. | -1.11 Billion JPY | 165.018% |
| SanBio Company Limited | -4.53 Billion JPY | 115.989% |
| Healios K.K. | -3.37 Billion JPY | 121.477% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 162.829% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 152.079% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 151.727% |
| StemRIM | -2.07 Billion JPY | 134.958% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 40.587% |
| FunPep Company Limited | -994 Million JPY | 173.01% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 181.656% |
| Stella Pharma Corporation | -760.3 Million JPY | 195.452% |
| TMS Co., Ltd. | -943.25 Million JPY | 176.938% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 193.595% |
| Cuorips Inc. | -588.48 Million JPY | 223.32% |
| K Pharma,Inc. | 366.05 Million JPY | -98.254% |
| Takara Bio Inc. | 3 Billion JPY | 75.833% |
| ReproCELL Incorporated | -409.29 Million JPY | 277.312% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | -6459.92% |
| StemCell Institute Inc. | 413.75 Million JPY | -75.398% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | -402.207% |
| CellSeed Inc. | -697.77 Million JPY | 204.005% |